Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 3 | 2013 | 323 | 0.980 |
Why?
|
| Trichosporonosis | 1 | 2024 | 8 | 0.940 |
Why?
|
| Acinetobacter Infections | 2 | 2013 | 26 | 0.810 |
Why?
|
| Acinetobacter baumannii | 2 | 2013 | 37 | 0.790 |
Why?
|
| Wound Infection | 1 | 2022 | 53 | 0.780 |
Why?
|
| Diabetic Foot | 1 | 2024 | 162 | 0.770 |
Why?
|
| Osteomyelitis | 1 | 2024 | 205 | 0.770 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2013 | 134 | 0.750 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 11 | 0.730 |
Why?
|
| Podiatry | 1 | 2021 | 7 | 0.730 |
Why?
|
| Immunization, Passive | 8 | 2024 | 120 | 0.700 |
Why?
|
| Communicable Diseases | 1 | 2022 | 160 | 0.680 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 218 | 0.660 |
Why?
|
| Ambulatory Care | 2 | 2022 | 386 | 0.610 |
Why?
|
| Hospitals, Psychiatric | 1 | 2012 | 68 | 0.400 |
Why?
|
| Carrier State | 1 | 2012 | 77 | 0.400 |
Why?
|
| Legionellosis | 1 | 2012 | 4 | 0.390 |
Why?
|
| Legionella | 1 | 2012 | 9 | 0.390 |
Why?
|
| Brain Abscess | 1 | 2012 | 50 | 0.370 |
Why?
|
| Infection Control | 1 | 2012 | 155 | 0.370 |
Why?
|
| Seasons | 1 | 2012 | 310 | 0.360 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 320 | 0.350 |
Why?
|
| Endocarditis, Bacterial | 1 | 2012 | 133 | 0.350 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 221 | 0.340 |
Why?
|
| Prosthesis-Related Infections | 1 | 2012 | 177 | 0.330 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 557 | 0.280 |
Why?
|
| Hospitalization | 4 | 2024 | 1777 | 0.280 |
Why?
|
| Mental Disorders | 1 | 2012 | 820 | 0.240 |
Why?
|
| Basidiomycota | 1 | 2024 | 11 | 0.240 |
Why?
|
| Gangrene | 1 | 2024 | 26 | 0.230 |
Why?
|
| Outpatients | 5 | 2024 | 251 | 0.230 |
Why?
|
| Aged | 6 | 2024 | 19703 | 0.220 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 42 | 0.210 |
Why?
|
| Urticaria | 1 | 2023 | 20 | 0.210 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2023 | 18 | 0.210 |
Why?
|
| JC Virus | 1 | 2023 | 30 | 0.210 |
Why?
|
| Antifungal Agents | 1 | 2024 | 288 | 0.190 |
Why?
|
| Humans | 20 | 2024 | 124602 | 0.190 |
Why?
|
| West Virginia | 1 | 2021 | 7 | 0.180 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 10 | 0.180 |
Why?
|
| Foot | 1 | 2021 | 61 | 0.180 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 1151 | 0.170 |
Why?
|
| Skin | 1 | 2022 | 520 | 0.160 |
Why?
|
| Wound Healing | 1 | 2022 | 456 | 0.150 |
Why?
|
| Neoplasms | 1 | 2013 | 2772 | 0.150 |
Why?
|
| Risk Factors | 3 | 2021 | 10270 | 0.140 |
Why?
|
| Middle Aged | 5 | 2024 | 26714 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2426 | 0.130 |
Why?
|
| Female | 7 | 2024 | 66491 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2013 | 3281 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2024 | 1637 | 0.120 |
Why?
|
| Adult | 7 | 2024 | 29440 | 0.110 |
Why?
|
| Skin Diseases, Infectious | 1 | 2012 | 25 | 0.100 |
Why?
|
| Pennsylvania | 1 | 2012 | 53 | 0.100 |
Why?
|
| Male | 6 | 2024 | 61198 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2012 | 32 | 0.100 |
Why?
|
| Endocardium | 1 | 2012 | 49 | 0.100 |
Why?
|
| Medical Audit | 1 | 2012 | 102 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 91 | 0.100 |
Why?
|
| Nursing Homes | 1 | 2012 | 92 | 0.100 |
Why?
|
| Levofloxacin | 1 | 2012 | 45 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 429 | 0.090 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 87 | 0.090 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 130 | 0.090 |
Why?
|
| Patient Admission | 1 | 2012 | 186 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 587 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2012 | 130 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 307 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2012 | 309 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 228 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 388 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 271 | 0.080 |
Why?
|
| Radiography | 1 | 2012 | 821 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2021 | 16317 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 496 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 372 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 336 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12324 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1108 | 0.080 |
Why?
|
| Cytokines | 2 | 2023 | 1291 | 0.070 |
Why?
|
| United States | 4 | 2023 | 10887 | 0.070 |
Why?
|
| Critical Care | 1 | 2012 | 657 | 0.070 |
Why?
|
| Echocardiography | 1 | 2012 | 1052 | 0.070 |
Why?
|
| Blood Donors | 1 | 2024 | 62 | 0.060 |
Why?
|
| Interleukin-7 | 1 | 2023 | 44 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 11 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 208 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 373 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 419 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 6533 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 409 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 777 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1119 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3553 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 190 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 468 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 2983 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 1586 | 0.040 |
Why?
|
| Young Adult | 1 | 2012 | 9014 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1018 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1431 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2047 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 19279 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1099 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6135 | 0.030 |
Why?
|